文献速递白血病造血干细胞移植与细胞治疗

人源化CD19 CAR-T细胞在复发或难治性急性淋巴细胞白血病儿童及年轻成人中的研究

Humanized CD19-Targeted Chimeric Antigen Receptor (CAR) T Cells in CAR-Naive and CAR-Exposed Children and Young Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia.
PubMed 文献 · J Clin Oncol · 2021-06-22

该试点临床试验评估了人源化CD19 CAR-T细胞(huCART19)在复发或难治性B-ALL儿童及年轻成人中的毒性、疗效和持续性。共74例患者接受治疗,分为CAR初治和再治疗两组;初治组1个月总缓解率98%(B-ALL为100%),再治疗组64%;初治组12和24个月无复发生存率分别为84%和74%,再治疗组为74%和58%。结论认为huCART19可获得持久缓解和长期持续性,包括既往CAR-T治疗失败者。

要点

  • huCART19在CAR初治B-ALL中1个月缓解率达100%,再治疗组为64%。
  • 细胞因子释放综合征发生率84%,4级占6.8%;神经毒性39%,3/4级占4%且均完全缓解。
  • 12个月无复发生存率初治组84%、再治疗组74%;24个月分别为74%和58%。

核心结论

  • HuCART19在复发或难治性B-ALL儿童及年轻成人中实现了持久缓解和长期持续性,包括既往CAR-T治疗失败者。

研究设计与样本

  • 试点临床试验,纳入74例1-29岁复发或难治性B-ALL(n=72)或B淋巴母细胞淋巴瘤(n=2)患者。
  • 分为CAR初治组(n=41)和再治疗组(n=33),监测毒性、缓解和huCART19持续性。

主要发现

  • 细胞因子释放综合征发生于62例(84%),4级5例(6.8%);神经毒性29例(39%),3或4级3例(4%),均完全缓解。
  • 输注后1个月总缓解率:CAR初治组98%(B-ALL为100%),再治疗组64%。
  • 6个月时huCART19持续性丢失概率:初治组27%(95%CI 14-41),再治疗组48%(95%CI 30-64)。
  • 6个月时B细胞恢复发生率:初治组15%(95%CI 6-28),再治疗组58%(95%CI 33-77)。
  • 12和24个月无复发生存率:初治组分别为84%(95%CI 72-97)和74%(95%CI 60-90);再治疗组分别为74%(95%CI 56-97)和58%(95%CI 37-90)。

临床怎么用

  • 对于复发或难治性B-ALL儿童及年轻成人,huCART19可考虑用于CAR初治及既往CAR-T治疗失败后的再治疗。
  • 治疗中需密切监测细胞因子释放综合征和神经毒性,多数神经毒性可完全缓解。

局限性

  • 为试点临床试验,样本量有限(n=74),需更大规模研究验证。
  • 研究纳入B-ALL和B淋巴母细胞淋巴瘤患者,后者仅2例,结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: CD19-targeted chimeric antigen receptor (CAR)-modified T cells demonstrate unprecedented responses in B-cell acute lymphoblastic leukemia (B-ALL); however, relapse remains a substantial challenge. Short CAR T-cell persistence contributes to this risk; therefore, strategies to improve persistence are needed. METHODS: We conducted a pilot clinical trial of a humanized CD19 CAR T-cell product (huCART19) in children and young adults with relapsed or refractory B-ALL (n = 72) or B-lymphoblastic lymphoma (n = 2), treated in two cohorts: with (retreatment, n = 33) or without (CAR-naive, n = 41) prior CAR exposure. Patients were monitored for toxicity, response, and persistence of huCART19. RESULTS: Seventy-four patients 1-29 years of age received huCART19. Cytokine release syndrome developed in 62 (84%) patients and was grade 4 in five (6.8%). Neurologic toxicities were reported in 29 (39%), three (4%) grade 3 or 4, and fully resolved in all cases. The overall response rate at 1 month after infusion was 98% (100% in B-ALL) in the CAR-naive cohort and 64% in the retreatment cohort. At 6 months, the probability of losing huCART19 persistence was 27% (95% CI, 14 to 41) for CAR-naive and 48% (95% CI, 30 to 64) for retreatment patients, whereas the incidence of B-cell recovery was 15% (95% CI, 6 to 28) and 58% (95% CI, 33 to 77), respectively. Relapse-free survival at 12 and 24 months, respectively, was 84% (95% CI, 72 to 97) and 74% (95% CI, 60 to 90) in CAR-naive and 74% (95% CI, 56 to 97) and 58% (95% CI, 37 to 90) in retreatment cohorts. CONCLUSION: HuCART19 achieved durable remissions with long-term persistence in children and young adults with relapsed or refractory B-ALL, including after failure of prior CAR T-cell therapy.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Myers RM, Li Y, Barz Leahy A, et al. Humanized CD19-Targeted Chimeric Antigen Receptor (CAR) T Cells in CAR-Naive and CAR-Exposed Children and Young Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia. J Clin Oncol. 2021. PMID: 34156874. doi:10.1200/JCO.20.03458

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。